Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status

Background: Approximately 50% of ovarian cancer patients harbour homologous recombination repair deficiencies. These deficiencies have been successfully targeted using poly (ADP-ribose) polymerase inhibitors (PARPi) particularly for patients harbouring BRCA1/2 mutations. The aim of this study is to...

Full description

Bibliographic Details
Main Authors: Sayeh Saravi, Zena Alizzi, Sabrina Tosi, Marcia Hall, Emmanouil Karteris
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cells
Subjects:
ovarian cancer
PARP inhibitors
rucaparib
BRCA mutation
homologous recombination deficiency
Online Access:https://www.mdpi.com/2073-4409/10/9/2434

Similar Items

Similar Items